Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTT in Peanut Allergic Patients
NCT05695261Phase 2Recruiting
- Start
- Jun 2023
- Primary completion
- Jan 2027
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in peanut allergy (3 arms). Primary endpoints: Changes in threshold of peanut reactivity during DBPCFC (<=100 mg to 300 mg peanut protein) at 4 months and Achievement of sustained unresponsiveness after 12 weeks of MTT. Started Jun 2023; status: recruiting.
02
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT05695261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05695261.